Skip to main content

Investment in MikrobiomikMikrobiomik has given CaixaBank CIB the exclusive mandate to assist in the search for potential investors for this round of capital, aimed primarily at Venture Capital, both national and international; Corporate Capital; institutional investors and professional Family Offices.

The funds raised will be used mainly to expand Mikrobiomik’s manufacturing capacity to meet the expected demand for the biological medicine MBK-01, for the treatment of primary or recurrent Clostridium difficile (ICD) as a first indication. It will also help to increase our current staff of 20 people, to accelerate other clinical trials the company has underway and to launch new projects currently in its pipeline.

Following the successful closure of our Phase III clinical trial for Clostridium difficile (ICD), with the aim of launching the first biological medicine based on human microbiota to the European market in the first half of 2025, it has launched this strategic investment round to raise between 6 and 10 million euros.



Expansión: Mikrobiomik hopes to raise up to 10 million to launch its first drug

Cinco Días: The startup Mikrobiomik hires CaixaBank for a financing round of up to 10 million